EGFR and non-small cell lung carcinoma: The ability of [6-O-methyl-11C]erlotinib to differentiate between primary and resistance mutations was assessed in Hsd:Athymic Nude-Fox1nu mice xenografted with four human NSCLC cell lines: QG56 (wild-type EGFR), HCC827 (De19 EGFR), H3255 (L858R), and H1975 (L858R/T790M) using μPET/CT.